AI-assisted, human-published
01/02/2024 /Funding Events
Graviton Bioscience Secures Funding to Advance Clinical Development of ROCK2 Inhibitors
Graviton Bioscience secures financing from Enavate Sciences, a portfolio company of Patient Square Capital, to advance the clinical development of ROCK2 inhibitors, including GV101, for treating serious fibrotic, inflammatory, and neurologic conditions.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com